Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.

MLA

Okamoto, Masato, et al. “Expression of Toll-like Receptor 4 on Dendritic Cells Is Significant for Anticancer Effect of Dendritic Cell-Based Immunotherapy in Combination with an Active Component of OK-432, a Streptococcal Preparation.” Cancer Research, vol. 64, no. 15, Aug. 2004, pp. 5461–70. EBSCOhost, https://doi.org/10.1158/0008-5472.CAN-03-4005.

APA

Okamoto, M., Furuichi, S., Nishioka, Y., Oshikawa, T., Tano, T., Ahmed, S. U., Takeda, K., Akira, S., Ryoma, Y., Moriya, Y., Saito, M., Sone, S., & Sato, M. (2004). Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Research, 64(15), 5461–5470. https://doi.org/10.1158/0008-5472.CAN-03-4005

Chicago

Okamoto, Masato, Sachiko Furuichi, Yasuhiko Nishioka, Tetsuya Oshikawa, Tomoyuki Tano, Sharif Uddin Ahmed, Kiyoshi Takeda, et al. 2004. “Expression of Toll-like Receptor 4 on Dendritic Cells Is Significant for Anticancer Effect of Dendritic Cell-Based Immunotherapy in Combination with an Active Component of OK-432, a Streptococcal Preparation.” Cancer Research 64 (15): 5461–70. doi:10.1158/0008-5472.CAN-03-4005.